Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI), Roberto Minutolo, Alessio Aghemo, Antonio Chirianni, Fabrizio Fabrizi, Loreto Gesualdo, Edoardo G. Giannini, Paolo Maggi, Vincenzo Montinaro, Ernesto Paoletti, Marcello Persico, Francesco Perticone, Salvatore Petta, Massimo Puoti, Giovanni Raimondo, Maria Rendina, Anna Linda Zignego

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

Original languageEnglish
Pages (from-to)141-168
JournalInfection
Volume47
Issue number1
DOIs
Publication statusPublished - 2019

Fingerprint

Nephrology
Virus Diseases
Internal Medicine
Chronic Renal Insufficiency
Hepacivirus
Communicable Diseases
Liver
Kidney
Population
Delivery of Health Care
Practice Management
Risk Management
Graft Survival
Proteinuria
Pharmaceutical Preparations
Kidney Transplantation
Italy
Renal Dialysis
Disease Progression
Liver Diseases

Keywords

  • Chronic kidney disease
  • Direct-acting antiviral agents
  • HCV in renal transplantation
  • HCV infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI), Minutolo, R., Aghemo, A., ... Zignego, A. L. (2019). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection, 47(1), 141-168. https://doi.org/10.1007/s15010-018-1209-2

Management of hepatitis C virus infection in patients with chronic kidney disease : position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). / on behalf of the Italian Society of Nephrology (SIN); the Italian Association for the Study of the Liver (AISF); the Italian Society of Infectious and Tropical Disease (SIMIT); the Italian Society of Internal Medicine (SIMI); Minutolo, Roberto; Aghemo, Alessio; Chirianni, Antonio; Fabrizi, Fabrizio; Gesualdo, Loreto; Giannini, Edoardo G.; Maggi, Paolo; Montinaro, Vincenzo; Paoletti, Ernesto; Persico, Marcello; Perticone, Francesco; Petta, Salvatore; Puoti, Massimo; Raimondo, Giovanni; Rendina, Maria; Zignego, Anna Linda.

In: Infection, Vol. 47, No. 1, 2019, p. 141-168.

Research output: Contribution to journalArticle

on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI), Minutolo, R, Aghemo, A, Chirianni, A, Fabrizi, F, Gesualdo, L, Giannini, EG, Maggi, P, Montinaro, V, Paoletti, E, Persico, M, Perticone, F, Petta, S, Puoti, M, Raimondo, G, Rendina, M & Zignego, AL 2019, 'Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)', Infection, vol. 47, no. 1, pp. 141-168. https://doi.org/10.1007/s15010-018-1209-2
on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI), Minutolo R, Aghemo A et al. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection. 2019;47(1):141-168. https://doi.org/10.1007/s15010-018-1209-2
on behalf of the Italian Society of Nephrology (SIN) ; the Italian Association for the Study of the Liver (AISF) ; the Italian Society of Infectious and Tropical Disease (SIMIT) ; the Italian Society of Internal Medicine (SIMI) ; Minutolo, Roberto ; Aghemo, Alessio ; Chirianni, Antonio ; Fabrizi, Fabrizio ; Gesualdo, Loreto ; Giannini, Edoardo G. ; Maggi, Paolo ; Montinaro, Vincenzo ; Paoletti, Ernesto ; Persico, Marcello ; Perticone, Francesco ; Petta, Salvatore ; Puoti, Massimo ; Raimondo, Giovanni ; Rendina, Maria ; Zignego, Anna Linda. / Management of hepatitis C virus infection in patients with chronic kidney disease : position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). In: Infection. 2019 ; Vol. 47, No. 1. pp. 141-168.
@article{17d597c1008d432291fe21f63ee8c55c,
title = "Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)",
abstract = "Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.",
keywords = "Chronic kidney disease, Direct-acting antiviral agents, HCV in renal transplantation, HCV infection",
author = "{on behalf of the Italian Society of Nephrology (SIN)} and {the Italian Association for the Study of the Liver (AISF)} and {the Italian Society of Infectious and Tropical Disease (SIMIT)} and {the Italian Society of Internal Medicine (SIMI)} and Roberto Minutolo and Alessio Aghemo and Antonio Chirianni and Fabrizio Fabrizi and Loreto Gesualdo and Giannini, {Edoardo G.} and Paolo Maggi and Vincenzo Montinaro and Ernesto Paoletti and Marcello Persico and Francesco Perticone and Salvatore Petta and Massimo Puoti and Giovanni Raimondo and Maria Rendina and Zignego, {Anna Linda}",
year = "2019",
doi = "10.1007/s15010-018-1209-2",
language = "English",
volume = "47",
pages = "141--168",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel GmbH",
number = "1",

}

TY - JOUR

T1 - Management of hepatitis C virus infection in patients with chronic kidney disease

T2 - position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

AU - on behalf of the Italian Society of Nephrology (SIN)

AU - the Italian Association for the Study of the Liver (AISF)

AU - the Italian Society of Infectious and Tropical Disease (SIMIT)

AU - the Italian Society of Internal Medicine (SIMI)

AU - Minutolo, Roberto

AU - Aghemo, Alessio

AU - Chirianni, Antonio

AU - Fabrizi, Fabrizio

AU - Gesualdo, Loreto

AU - Giannini, Edoardo G.

AU - Maggi, Paolo

AU - Montinaro, Vincenzo

AU - Paoletti, Ernesto

AU - Persico, Marcello

AU - Perticone, Francesco

AU - Petta, Salvatore

AU - Puoti, Massimo

AU - Raimondo, Giovanni

AU - Rendina, Maria

AU - Zignego, Anna Linda

PY - 2019

Y1 - 2019

N2 - Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

AB - Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

KW - Chronic kidney disease

KW - Direct-acting antiviral agents

KW - HCV in renal transplantation

KW - HCV infection

UR - http://www.scopus.com/inward/record.url?scp=85053877177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053877177&partnerID=8YFLogxK

U2 - 10.1007/s15010-018-1209-2

DO - 10.1007/s15010-018-1209-2

M3 - Article

AN - SCOPUS:85053877177

VL - 47

SP - 141

EP - 168

JO - Infection

JF - Infection

SN - 0300-8126

IS - 1

ER -